- Home
- DOUG vs PBYI Comparison
DOUG vs PBYI Comparison
Compare DOUG & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOUG
- PBYI
- Stock Information
- Founded
- DOUG 1911
- PBYI 2010
- Country
- DOUG United States
- PBYI United States
- Employees
- DOUG N/A
- PBYI N/A
- Industry
- DOUG Building operators
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- DOUG Real Estate
- PBYI Health Care
- Exchange
- DOUG Nasdaq
- PBYI Nasdaq
- Market Cap
- DOUG 161.5M
- PBYI 171.7M
- IPO Year
- DOUG N/A
- PBYI N/A
- Fundamental
- Price
- DOUG $3.11
- PBYI $4.52
- Analyst Decision
- DOUG
- PBYI Strong Buy
- Analyst Count
- DOUG 0
- PBYI 1
- Target Price
- DOUG N/A
- PBYI $7.00
- AVG Volume (30 Days)
- DOUG 503.2K
- PBYI 525.6K
- Earning Date
- DOUG 11-05-2025
- PBYI 11-06-2025
- Dividend Yield
- DOUG N/A
- PBYI N/A
- EPS Growth
- DOUG N/A
- PBYI 434.29
- EPS
- DOUG N/A
- PBYI 0.97
- Revenue
- DOUG $1,034,406,000.00
- PBYI $238,062,000.00
- Revenue This Year
- DOUG $17.61
- PBYI N/A
- Revenue Next Year
- DOUG N/A
- PBYI N/A
- P/E Ratio
- DOUG N/A
- PBYI $4.64
- Revenue Growth
- DOUG 8.69
- PBYI 8.63
- 52 Week Low
- DOUG $1.35
- PBYI $2.32
- 52 Week High
- DOUG $3.20
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- DOUG 66.95
- PBYI 47.80
- Support Level
- DOUG $2.58
- PBYI $4.30
- Resistance Level
- DOUG $2.95
- PBYI $4.72
- Average True Range (ATR)
- DOUG 0.15
- PBYI 0.26
- MACD
- DOUG 0.03
- PBYI -0.10
- Stochastic Oscillator
- DOUG 88.32
- PBYI 19.30
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees. It derives revenue from Real Estate Brokerage segment.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.